PharVision Advisers’s Delek US DK Stock Holding History

PharVision Advisers’s Portfolio DK Stock Details DK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,407	Closed	-$724K	–	255
2025 Q4	$724K	Buy	+24,407	New	+$871K	0.37%	2

Other funds holding DK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PharVision Advisers's DK Position: Q1 2026 in Review

PharVision Advisers sold out of Delek US (DK) in Q1 2026, closing a stake of 24,407 shares — an estimated $724K sold.

PharVision Advisers first reported a position in DK in Q4 2025 and held it in 1 quarter. The position peaked at $724K in Q4 2025. 278 funds tracked by Wall St. Rank hold DK as of Q1 2026.

PharVision Advisers reported no remaining Delek US position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 24,407 Delek US shares in Q1 2026, an estimated $724K.
PharVision Advisers first reported a position in Delek US in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Delek US position peaked at $724K in Q4 2025.
278 funds tracked by Wall St. Rank held Delek US as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.